BioCardia was founded in 2002 to develop biointerventional solutions for heart failure, chronic myocardial ischemia and acute myocardial infarction and is headquartered in San Carlos, California.
|
January 10, 2014
BioCardia Receives CE Mark for New Helix™ Transendocardial Delivery Catheter
November 18, 2013
Phase II TAC-HFT Trial Shows Excellent Safety Profile, Suggests Efficacy, for Transendocardial Delivery of Two Types of Autologous Cells for Ischemic Heart Failure
|
October 28, 2013
Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
July 13, 2013
BioCardia’s Helical Infusion Catheter completes case number 200 with an excellent safety profile
|
